Mitochondrial cytochrome c oxidase subunit II variations predict adverse prognosis in cytogenetically normal acute myeloid leukaemia
- 4 July 2013
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 91 (4) , 295-303
Abstract
Alterations in the two catalytic genes cytochrome c oxidase subunits I and II (COI and COII) have recently been suggested to have an adverse impact on prognosis in patients with acute myeloid leukaemia (AML). In order to explore this in further detail, we sequenced these two mitochondrial genes in diagnostic bone marrow or blood samples in 235 patients with AML. In 37 (16%) patients, a non-synonymous variation in either COI or COII could be demonstrated. No patients harboured both COI and COII non-synonymous variations. Twenty-four (10%) patients had non-synonymous variations in COI, whereas 13 (6%) patients had non-synonymous variations in COII. The COI and COII are essential subunits of cytochrome c oxidase that is the terminal enzyme in the oxidative phosphorylation complexes. In terms of disease course, we observed that in patients with a normal cytogenetic analysis at disease presentation (CN-AML) treated with curative intent, the presence of a non-synonymous variation in the COII was an adverse prognostic marker for both overall survival and disease-free survival (DFS) in both univariate (DFS; hazard ratio (HR) 4.4, P = 0.006) and multivariate analyses (DFS; HR 7.2, P = 0.001). This is the first demonstration of a mitochondrial aberration playing an adverse prognostic role in adult AML, and we argue that its role as a potentially novel adverse prognostic marker in the subset of CN-AML should be explored further.Keywords
This publication has 59 references indexed in Scilit:
- Molecular markers in acute myeloid leukaemiaInternational Journal of Hematology, 2012
- TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study GroupJournal of Clinical Oncology, 2012
- Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic ImplicationsJournal of Clinical Oncology, 2011
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsBlood, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid LeukemiaNew England Journal of Medicine, 2008
- Acute myeloid leukaemiaThe Lancet, 2006
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood, 2006
- Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotypeBlood, 2005
- Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal KaryotypeNew England Journal of Medicine, 2005